



## **Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024**

May 7, 2024

FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens JMP Life Sciences Conference 2024 on Tuesday, May 14, 2024 at 1:30 p.m. ET.

A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at <http://ir.ternspharma.com>. A replay of the webcast will be archived on Terns' website for 30 days following the event.

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR- $\beta$  agonist, and a preclinical GIPR modulator program. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

### **Contacts for Terns**

#### **Investors**

Justin Ng

[investors@ternspharma.com](mailto:investors@ternspharma.com)

#### **Media**

Jenna Urban

Berry & Company Public Relations

[media@ternspharma.com](mailto:media@ternspharma.com)